- Home
- ZUMZ vs LUNG Comparison
ZUMZ vs LUNG Comparison
Compare ZUMZ & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZUMZ
- LUNG
- Stock Information
- Founded
- ZUMZ 1978
- LUNG 1995
- Country
- ZUMZ United States
- LUNG United States
- Employees
- ZUMZ N/A
- LUNG N/A
- Industry
- ZUMZ Clothing/Shoe/Accessory Stores
- LUNG Industrial Specialties
- Sector
- ZUMZ Consumer Discretionary
- LUNG Health Care
- Exchange
- ZUMZ Nasdaq
- LUNG Nasdaq
- Market Cap
- ZUMZ 274.4M
- LUNG 299.3M
- IPO Year
- ZUMZ 2005
- LUNG 2020
- Fundamental
- Price
- ZUMZ $15.23
- LUNG $7.35
- Analyst Decision
- ZUMZ Hold
- LUNG Strong Buy
- Analyst Count
- ZUMZ 2
- LUNG 7
- Target Price
- ZUMZ $22.00
- LUNG $12.64
- AVG Volume (30 Days)
- ZUMZ 397.1K
- LUNG 269.0K
- Earning Date
- ZUMZ 03-13-2025
- LUNG 04-30-2025
- Dividend Yield
- ZUMZ N/A
- LUNG N/A
- EPS Growth
- ZUMZ N/A
- LUNG N/A
- EPS
- ZUMZ N/A
- LUNG N/A
- Revenue
- ZUMZ $889,202,000.00
- LUNG $83,789,000.00
- Revenue This Year
- ZUMZ $3.43
- LUNG $17.96
- Revenue Next Year
- ZUMZ $1.97
- LUNG $18.35
- P/E Ratio
- ZUMZ N/A
- LUNG N/A
- Revenue Growth
- ZUMZ 1.57
- LUNG 22.01
- 52 Week Low
- ZUMZ $12.67
- LUNG $5.46
- 52 Week High
- ZUMZ $31.37
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- ZUMZ 55.34
- LUNG 46.66
- Support Level
- ZUMZ $14.23
- LUNG $7.65
- Resistance Level
- ZUMZ $15.37
- LUNG $7.97
- Average True Range (ATR)
- ZUMZ 0.77
- LUNG 0.44
- MACD
- ZUMZ 0.27
- LUNG -0.08
- Stochastic Oscillator
- ZUMZ 94.81
- LUNG 33.04
About ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.